常宝股份(002478) - 2024 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2024 was CNY 1,420,125,907.43, a decrease of 14.24% compared to the same period last year[2] - Net profit attributable to shareholders was CNY 85,365,774.04, down 50.18% year-on-year[2] - Net profit excluding non-recurring items was CNY 94,989,122.68, a decline of 46.08% compared to the previous year[2] - Basic earnings per share for Q3 2024 were CNY 0.10, a decrease of 50.00% compared to the same period last year[2] - Total operating revenue for the period was CNY 4,224,507,623.37, a decrease of 17.4% compared to CNY 5,115,119,029.67 in the previous period[15] - Net profit for the period was CNY 433,621,178.81, a decline of 32.0% from CNY 637,431,820.61 in the previous period[16] - Earnings per share (EPS) decreased to CNY 0.46 from CNY 0.70 in the previous period, reflecting a 34.3% drop[17] - The total comprehensive income attributable to the parent company was CNY 413,945,320.84, down from CNY 622,245,679.23 in the previous period[17] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,829,283,028.18, a slight increase of 0.13% from the end of the previous year[2] - The company reported a total asset of RMB 7,829,283,028.18 as of September 30, 2024, showing a slight increase from RMB 7,819,431,790.19 at the beginning of the period[12]. - The company’s total liabilities decreased to RMB 2,203,022,792.86 from RMB 2,409,049,132.45, indicating a reduction of about 8.55%[13]. - Total assets and equity amounted to CNY 7,829,283,028.18 and CNY 5,626,260,235.32 respectively, showing stability in the company's financial position[16] Shareholder Equity - Shareholders' equity attributable to the parent company increased to CNY 5,422,150,293.77, up 3.70% from the previous year[2] - The company’s total equity decreased slightly from RMB 5,626,260,895.74 to RMB 5,626,260,235.32, reflecting a marginal decline[13]. - The minority interest in equity increased to CNY 204,109,941.55 from CNY 181,829,093.63, indicating growth in minority shareholders' equity[16] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 203,300,188.29, down 31.65% year-on-year[2] - Operating cash flow for the current period is ¥203,300,188.29, a decrease of 31.7% from ¥297,449,500.79 in the previous period[18] - Cash inflow from operating activities totals ¥4,295,672,966.96, slightly down from ¥4,320,632,833.02 in the previous period[18] - Cash outflow for purchasing goods and services is ¥3,571,708,443.41, an increase of 1.5% from ¥3,511,008,297.35 in the previous period[18] - Cash and cash equivalents increased to RMB 1,961,828,352.16 from RMB 1,700,305,019.44, reflecting a growth of approximately 15.36%[12]. - Cash and cash equivalents at the end of the period amount to ¥1,303,028,233.50, down from ¥1,532,882,044.79 in the previous period[19] Investment Activities - The company reported a decrease in investment income of CNY 9,597,900, a decline of 124.16% year-on-year[6] - Total cash inflow from investment activities is ¥972,124,100.13, compared to ¥820,852,487.97 in the previous period, reflecting an increase of 18.4%[19] - Cash outflow for investment activities totals ¥825,018,919.92, up from ¥398,342,477.47 in the previous period, indicating a substantial increase[19] - Cash received from other investment activities is ¥807,113,096.74, significantly higher than ¥65,285,524.69 in the previous period[18] Other Financial Metrics - The company reported a decrease in research and development expenses to CNY 153,216,127.30, down 20.9% from CNY 193,612,257.32 in the previous period[15] - Other income increased significantly to CNY 24,363,120.31 from CNY 1,498,765.71 in the previous period, indicating improved non-operating revenue[16] - The company has outstanding receivables of RMB 110,330,014.20 related to medical asset sales, which remain unpaid as of April 30, 2024[11]. - The company repurchased a total of 4,880,900 shares at a total cost of RMB 22,923,877.63, with a maximum repurchase price set at RMB 6.50 per share[10]. - The company plans to utilize repurchased shares for employee stock ownership plans or equity incentive plans[10].